Heterogeneity in the clinical presentation, severity, and evolution of EGE, together with its low prevalence, has made it difficult to establish ideal treatment strategies for these patients.

Eosinophilic gastroenteritis (EGE) is characterized by dense eosinophilic inflammation of one or several digestive tract sections. The symptoms include abdominal pain, weight loss, vomiting and ...

Advanced adenomas were associated with an increased risk of all-cause mortality, a cohort study from Minnesota found. (JAMA ...

SELARSDI is approved for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults and ...

Coffee by itself does not irritate ulcerative colitis. But this caffeine drink can stimulate the colon, which can be more uncomfortable for those living with the condition. Share on Pinterest ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDItm for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination ...

Pfizer placed a $6.7 billion bet on the outcome of two phase 3 trials of Arena Pharmaceuticals' etrasimod in ulcerative colitis (UC ... from Bristol-Myers Squibb. Treatment with etrasimod in ...

About 600 people in England could benefit from the therapy per year, according to NICE, which called the one-time CAR-T treatment "a ... 2023 to treat ulcerative colitis, the agency has now ...

3, 2025 — A multi-institutional study has identified one of the allergens responsible for eosinophilic esophagitis ... is more effective than the current treatment of steroid tablets, reducing ...

Specifically, the drug is indicated in both countries as an add-on treatment for patients with inadequately controlled COPD and an eosinophilic phenotype - about 300,000 patients in the US.